UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[X]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2017


or


[  ]  Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.


Commission File Number: 000-54500


Cell MedX Corp.

(Exact name of registrant as specified in its charter)


Nevada

 

38-3939625

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)


123 W. Nye Ln, Suite 446

Carson City, NV

 

89706

(Address of principal executive offices)

 

(Zip code)


(844) 238-2692

(Registrant’s telephone number, including area code)


N/A

(Former name, former address and former fiscal year, if changed since last report)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]  No [  ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  Yes [X]  No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer  [  ]

 

Accelerated filer  [  ]

Non-accelerated filer  [  ]

 

Smaller Reporting Company [X]

 

 

Emerging Growth Company [  ]


Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.)  Yes [  ]  No [X]


The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of January 16, 2018 was 44,042,749.





CONTENTS



PART I - FINANCIAL INFORMATION

1

Item 1. Financial Statements

1

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

2

Item 3. Quantitative and Qualitative Disclosure about Market Risk

8

Item 4. Controls and Procedures

8

PART II - OTHER INFORMATION

9

Item 1. Legal Proceedings

9

Item 1A. Risk Factors

9

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

12

Item 3. Defaults upon Senior Securities

13

Item 4. Mine Safety Disclosures

13

Item 5. Other Information

13

Item 6. Exhibits

13

SIGNATURES

16

































ii




PART I - FINANCIAL INFORMATION


Item 1. Financial Statements


The accompanying unaudited consolidated interim financial statements of Cell MedX Corp. as at November 30, 2017, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.


Operating results for the three and six months ended November 30, 2017, are not necessarily indicative of the results that can be expected for the year ending May 31, 2018.


As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.































1




CELL MEDX CORP.

CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)



 

 

November 30, 2017

May 31, 2017

 

 

(Unaudited)

 

ASSETS

 

 

 

 

 

 

 

Current assets

 

 

 

  Cash

 

$

108,368

$

67,494

  Inventory

 

 

29,399

 

8,161

  Other current assets

 

 

122,556

 

24,502

Total current assets

 

 

260,323

 

100,157

 

 

 

 

 

 

  Equipment

 

 

116,014

 

193,571

Total assets

 

$

376,337

$

293,728

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

  Accounts payable

 

$

514,745

$

447,600

  Accrued liabilities

 

 

5,481

 

80,200

  Due to related parties

 

 

252,836

 

342,847

  Notes and advances payable

 

 

98,731

 

541,298

  Unearned revenue

 

 

109,832

 

51,110

Total liabilities

 

 

981,625

 

1,463,055

 

 

 

 

 

 

STOCKHOLDERS' DEFICIT

 

 

 

 

 

  Common stock, $0.001 par value, 300,000,000 shares authorized;

    44,042,749 and 40,244,605 shares issued and outstanding at

    November 30, 2017 and May 31, 2017, respectively

 

 

44,043

 

40,245

  Additional paid-in capital

 

 

4,869,300

 

3,294,224

  Accumulated deficit

 

 

(5,518,708)

 

(4,504,043)

  Accumulated other comprehensive income

 

 

77

 

247

Total stockholders' deficit

 

 

(605,288)

 

(1,169,327)

Total liabilities and stockholders' deficit

 

$

376,337

$

293,728













The accompanying notes are an integral part of these unaudited interim consolidated financial statements.



F-1




CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(Unaudited)



 

 

Three Months Ended

November 30,

 

Six Months Ended

November 30,

 

 

2017

2016

 

2017

2016

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

  Sales

 

$

-

$

336

 

$

-

$

5,704

  Cost of goods sold

 

 

-

 

180

 

 

-

 

3,591

Gross margin

 

 

-

 

156

 

 

-

 

2,113

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

  Amortization

 

 

38,434

 

18,510

 

 

77,557

 

36,521

  Consulting fees

 

 

61,422

 

75,607

 

 

644,881

 

150,747

  General and administrative expenses

 

 

33,586

 

51,239

 

 

88,061

 

95,463

  Research and development costs

 

 

41,491

 

67,173

 

 

88,994

 

140,025

  Stock-based compensation

 

 

6,130

 

29,306

 

 

106,931

 

78,203

Total operating expenses

 

 

181,063

 

241,835

 

 

1,006,424

 

500,959

 

 

 

 

 

 

 

 

 

 

 

Other items

 

 

 

 

 

 

 

 

 

 

  Accretion expense

 

 

-

 

(7,473)

 

 

-

 

(13,730)

  Interest

 

 

(327)

 

(5,596)

 

 

(8,241)

 

(20,991)

  Loss on settlement of debt

 

 

-

 

(805,353)

 

 

-

 

(805,353)

Net loss

 

 

(181,390)

 

(1,060,101)

 

 

(1,014,665)

 

(1,338,920)

 

 

 

 

 

 

 

 

 

 

 

  Unrealized foreign exchange translation

    gain (loss)

 

 

1,464

 

1,881

 

 

(170)

 

1,912

Comprehensive loss

 

$

(179,926)

$

(1,058,220)

 

$

(1,014,835)

$

(1,337,008)

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share

 

 

 

 

 

 

 

 

 

 

  Basic and diluted

 

$

(0.00)

$

(0.03)

 

$

(0.02)

$

(0.04)

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares

  outstanding - basic and diluted

 

 

41,997,595

 

36,014,128

 

 

41,116,310

 

33,493,364












The accompanying notes are an integral part of these unaudited interim consolidated financial statements.



F-2




CELL MEDX CORP.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(EXPRESSED IN US DOLLARS)

(Unaudited)



 

 

 

Obligation

Additional

 

Accumulated

Other

 

 

Common Stock

to Issue

Paid-in

Deficit

Comprehensive

 

 

Shares

Amount

Shares

Capital

Accumulated

Income

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - May 31, 2016

31,000,000

$

31,000

$

75,000

$

1,734,498

$

(3,254,597)

$

1,547

$

(1,412,552)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

-

 

-

 

-

 

78,203

 

-

 

-

 

78,203

Shares issued for cash

2,383,333

 

2,383

 

-

 

355,117

 

-

 

-

 

357,500

Shares issued for debt

6,711,272

 

6,712

 

-

 

1,805,332

 

-

 

-

 

1,812,044

Issuance of shares subscribed

150,000

 

150

 

(75,000)

 

74,850

 

-

 

-

 

-

Net loss for the six months ended November 30, 2016

-

 

-

 

-

 

-

 

(1,338,920)

 

-

 

(1,338,920)

Translation to reporting currency

-

 

-

 

-

 

-

 

-

 

1,912

 

1,912

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - November 30, 2016

40,244,605

 

40,245

 

-

 

4,048,000

 

(4,593,517)

 

3,459

 

(501,813)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

-

 

-

 

-

 

39,280

 

-

 

-

 

39,280

Shares issued for debt

-

 

-

 

-

 

(805,353)

 

-

 

-

 

(805,353)

Gain on divesting of subsidiary

-

 

-

 

-

 

12,297

 

-

 

-

 

12,297

Net loss for the six months ended May 31, 2017

-

 

-

 

-

 

-

 

89,474

 

-

 

89,474

Translation to reporting currency

-

 

-

 

-

 

-

 

-

 

(3,212)

 

(3,212)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - May 31, 2017

40,244,605

 

40,245

 

-

 

3,294,224

 

(4,504,043)

 

247

 

(1,169,327)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

-

 

-

 

-

 

106,931

 

-

 

-

 

106,931

Options issued for consulting fees

-

 

-

 

-

 

522,407

 

-

 

-

 

522,407

Shares issued for cash

1,480,000

 

1,480

 

-

 

368,520

 

-

 

-

 

370,000

Shares issued for debt

2,318,144

 

2,318

 

-

 

577,218

 

-

 

-

 

579,536

Net loss for the six months ended November 30, 2017

-

 

-

 

-

 

-

 

(1,014,665)

 

-

 

(1,014,665)

Translation to reporting currency

-

 

-

 

-

 

-

 

-

 

(170)

 

(170)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - November 30, 2017

44,042,749

$

44,043

$

-

$

4,869,300

$

(5,518,708)

$

77

$

(605,288)














The accompanying notes are an integral part of these unaudited interim consolidated financial statements.



F-3




CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(Unaudited)



 

Six Months Ended

November 30,

 

2017

 

2016

 

 

 

 

Cash flows used in operating activities:

 

 

 

  Net loss

$

(1,014,665)

 

$

(1,338,920)

  Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

    Accretion expense

 

-

 

 

13,730

    Accrued interest on notes payable

 

8,241

 

 

20,991

    Amortization

 

77,557

 

 

36,521

    Consulting fees - non-cash

 

522,407

 

 

-

    Loss on settlement of debt

 

-

 

 

805,353

    Unrealized foreign exchange

 

5,127

 

 

(4,264)

    Stock-based compensation

 

106,931

 

 

78,203

  Changes in operating assets and liabilities:

 

 

 

 

 

    Inventory

 

(21,133)

 

 

797

    Other current assets

 

(99,028)

 

 

(40,213)

    Accounts payable

 

66,244

 

 

12,358

    Accrued liabilities

 

(74,719)

 

 

(29,553)

    Unearned revenue

 

59,588

 

 

11,471

    Due to related parties

 

30,246

 

 

30,221

Net cash flows used in operating activities

 

(333,204)

 

 

(403,305)

 

 

 

 

 

 

Cash flows used in investing activities:

 

 

 

 

 

  Acquisition of equipment

 

-

 

 

(14,940)

Net cash used in investing activities

 

-

 

 

(14,940)

 

 

 

 

 

 

Cash flows provided by financing activities:

 

 

 

 

 

  Advances (repaid) payable

 

(22,704)

 

 

2,684

  Proceeds from notes payable

 

25,318

 

 

148,754

  Proceeds from subscription to shares

 

370,000

 

 

357,500

Net cash provided by financing activities

 

372,614

 

 

508,938

 

 

 

 

 

 

Effects of foreign currency exchange on cash

 

1,464

 

 

(274)

  Increase in cash

 

40,874

 

 

90,419

  Cash, beginning

 

67,494

 

 

27,561

  Cash, ending

$

108,368

 

$

117,980

 

 

 

 

 

 

Non-cash financing transactions:

 

 

 

 

 

  Settlement of debt with shares

$

579,536

 

$

1,812,044





The accompanying notes are an integral part of these unaudited interim consolidated financial statements.



F-4



CELL MEDX CORP.

NOTES TO THE UNAUDITED INTERIM

CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

NOVEMBER 30, 2017


NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS


Cell MedX Corp. (the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia.


The Company is in an early development stage focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.



Unaudited Interim Financial Statements

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2017, included in the Company’s Annual Report on Form 10-K, filed with the SEC. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended November 30, 2017, are not necessarily indicative of the results that may be expected for the year ending May 31, 2018.




Going concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2017, the Company has not achieved profitable operations and has accumulated a deficit of $5,518,708. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.


NOTE 2 - RELATED PARTY TRANSACTIONS


Amounts due to related parties, other than notes payable to related parties (Note 6) at November 30, 2017 and May 31, 2017:


 

November 30,

2017

 

May 31,

2017

Due to the Chief Executive Officer (“CEO”) and President (Note 7)

$

10,800

 

$

109,453

Due to the Chief Financial Officer (“CFO”)

 

15,196

 

 

9,777

Due to the Vice President (“VP”), Technology and Operations

 

59,025

 

 

55,781

Due to the Chief Medical Officer

 

81,059

 

 

81,059

Due to the former VP, Corporate Strategy

 

86,756

 

 

86,777

Due to related parties

$

252,836

 

$

342,847

These amounts are unsecured, due on demand and bear no interest.




F-5



During the six-month periods ended November 30, 2017 and 2016, the Company had the following transactions with related parties:


 

November 30,

2017

 

November 30,

2016

Management fees incurred to the CEO and President

$

21,600

 

$

21,600

Stock-based compensation incurred to the CEO and President

 

--

 

 

11,600

Management fees incurred to the CFO

 

6,000

 

 

6,000

Stock-based compensation  incurred to the CFO (Note 7)

 

89,556

 

 

--

Consulting fees incurred to the former VP, Corporate Strategy

 

--

 

 

25,178

Consulting fees incurred to the VP, Technology and Operations

 

23,475

 

 

25,178

Stock-based compensation  incurred to the Chief Medical Officer

 

17,375

 

 

66,603

Accrued interest expense incurred to a significant shareholder (Note 6)

 

3,170

 

 

5,549

Accretion expense associated with a loan agreement entered into with a

significant shareholder (Note 6)

 

--

 

 

13,730

Total transactions with related parties

$

161,176

 

$

175,438


NOTE 3 - EQUIPMENT


Amortization schedule for the equipment at November 30, 2017 and May 31, 2017:


 

November 30, 2017

 

May 31, 2017

Book value, beginning of the period

$

193,571

 

$

207,083

Changes during the period

 

--

 

 

109,534

Amortization

 

 (77,557)

 

 

 (123,046)

Book value, end of the period

$

116,014

 

$

193,571


NOTE 4 - INVENTORY


As at November 30, 2017, the inventory consisted of supplies held for resale, and was valued at $29,399 (May 31, 2017 - $8,161). The Company uses lower of cost or net realizable value to determine the book value of the inventory at reporting date.


As at November 30, 2017, $18,556 included in inventory was attributed to work in progress (May 31, 2017 - $3,478).


NOTE 5 - UNEARNED REVENUE


During the six-month period ended November 30, 2017, the Company received $59,588 (CAD$75,000) deposit on a distribution contract. During the year ended May 31, 2017, the Company received $40,000 and $11,259 (CAD$15,000) in deposits on its eBalance Pro devices.


As at November 30, 2017, the Company had recorded a total of $109,832 in unearned revenue comprised of the deposits on the distribution contract and on eBalance Pro devices.


NOTE 6 - NOTES AND ADVANCES PAYABLE


The tables below summarize the short-term loans and advances outstanding as at November 30, 2017 and May 31, 2017:


As at November 30, 2017

Principal

Outstanding

Interest Rate

per Annum

 

Accrued

Interest

Total Book

Value

$

6,000

6%

Non-convertible

$

41

$

6,041

 

79,721

6%

Former Related Party

 

1,317

 

81,038

 

11,652

0%

Advances

 

--

 

11,652

$

97,373

 

 

$

1,358

$

98,731



F-6




As at May 31, 2017

Principal

Outstanding

Interest Rate

per Annum

 

Accrued

Interest / Accretion

Total Book

Value

$

382,484

6%

Non-convertible

$

6,727

$

389,211

 

61,748

6%

Former Related Party

 

2,241

 

63,989

 

50,000

6%

Term Loan - Former Related Party

 

3,775

 

53,775

 

34,323

0%

Advances

 

--

 

34,323

$

528,555

 

 

$

12,743

$

541,298


Loan Agreements

During the six-month period ended November 30, 2017, the Company entered into a loan agreement with Mr. Richard Jeffs (“Mr. Jeffs”), a major shareholder, for a total of $19,318 (CAD$25,000) (May 31, 2017 - $104,209) (the “Jeffs Loan”). The Jeffs Loan bears interest at 6% per annum, is unsecured and is payable on demand.


On September 15, 2017, the Company received a notice from Mr. Jeffs that he had assigned the rights to $7,984 due to him under the demand notes payable to a certain unaffiliated party. The assignee notified the Company of her intention to convert the debt acquired by her from Mr. Jeffs into the shares of the Company’s common stock as part of the debt restructuring initiative (the “Debt Restructuring”), which was completed on October 12, 2017 (Note 7).


Term Loan with Richard Jeffs

On March 3, 2016, the Company entered into a loan agreement (the “Term Loan Agreement”) with Mr. Jeffs for a loan in the principal amount of $50,000 maturing March 3, 2017, with interest payable at a rate of 6% per annum (the “Term Loan”).  As additional consideration for the Term Loan, the Company issued to Mr. Jeffs share purchase warrants (the “Warrants”) for the purchase of up to 2,000,000 shares of the Company’s common stock, exercisable for a period of five years at a price of $0.15 per share if exercised during the first year, $0.25 per share if exercised during the second year, $0.40 per share if exercised during the third year, $0.60 per share if exercised during the fourth year and $0.75 per share if exercised during the fifth year. The Warrants were determined to be detachable from the debt instrument, as the debt instrument did not have to be surrendered to exercise the Warrants. Pursuant to the guidance provided by ASC 470-20-25-2, proceeds from the Term Loan were allocated to the principal and stock purchase warrants based on the relative fair values of the two elements. The portion of the proceeds allocated to the Warrants was $25,000 and was recorded to additional paid-in capital.


The Term Loan had an effective interest rate of 77.51%, which was due primarily to the recording of non-cash accretion interest.


At March 3, 2016, the fair value of Warrants was valued using the Black-Scholes Option pricing model using the following assumptions:


 

At March 3, 2016

Expected Warrant Life

5 years

Risk-Free Interest Rate

1.33%

Expected Dividend Yield

Nil

Expected Stock Price Volatility

16%


On September 15, 2017, the Company received a notice from Mr. Jeffs that he had assigned the rights to the Term Loan and interest accrued thereon to two unaffiliated parties. The assignees notified the Company of their intention to convert the debt acquired by them from Mr. Jeffs into the shares of the Company’s common stock as part of the Debt Restructuring, which was completed on October 12, 2017 (Note 7).


Debt Restructuring


On October 12, 2017, the Company completed its Debt Restructuring by issuing a total of 1,837,128 shares on conversion of $459,282 in debt owed under the notes payable (Note 7).


Advances Payable

During the six-month period ended November 30, 2017, the Company repaid $22,704 (net of $9,936 advanced during the period) in non-interest bearing advances. The advances were unsecured and payable on demand.



F-7




Interest Expense

During the six-month period ended November 30, 2017, the Company recorded $8,241 (2016 - $20,991) in interest expense associated with its liabilities under the notes and advances payable. Of this amount $741 (2016 - $nil) was associated with interest recorded on the Term Loan with Mr. Jeffs and $2,429 (2016 - $5,549) with demand notes payable issued to Mr. Jeffs.


NOTE 7 - SHARE CAPITAL


On October 12, 2017, the Company closed a first tranche of its non-brokered private placement offering (the “Offering”) at a price of $0.25 per Unit, by issuing 1,480,000 Units for total gross proceeds of $370,000.


Each Unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of three years after closing at an exercise price of $0.50 per share if exercised during the first year, $1.00 per share if exercised during the second year, and $1.50 per share if exercised during the third year.


On October 12, 2017, the Company completed its debt restructuring initiative by converting a total of $459,282 the Company owed under its notes payable and $120,254 under services payable to its director, former CEO and President into 2,318,144 shares of the Company’s common stock at $0.25 per share.


Options


On August 24, 2017, the board of directors of the Company granted options to purchase up to 300,000 common shares of the Company to its CFO and up to 1,750,000 common shares of the Company to its consultants. The options vested immediately and may be exercised at a price of $0.35 per share for a period of five years expiring on August 24, 2022.


The fair values of the options granted to the CFO and to the consultants were calculated to be $89,556 and $522,407, respectively, and were determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:


 

At August 24, 2017

Expected Life of Options

5 years

Risk-Free Interest Rate

1.78%

Expected Dividend Yield

Nil

Expected Stock Price Volatility

187%


The changes in the number of stock options outstanding during the six-month period ended November 30, 2017, and for the year ended May 31, 2017 are as follows:


 

Six months ended

November 30, 2017

 

Year ended

May 31, 2017

 

Number of

options

Weighted

average

exercise

price

 

Number of

options

Weighted

average

exercise

price

Options outstanding, beginning

7,550,000

$

0.35

 

25,050,000

$

0.14

Options granted

2,050,000

$

0.35

 

--

 

n/a

Options expired

(150,000)

$

0.20

 

--

 

n/a

Options cancelled

--

$

n/a

 

 (17,500,000)

$

0.05

Options outstanding, ending

9,450,000

$

0.35

 

7,550,000

$

0.35

Options exercisable, ending

9,250,000

$

0.35

 

6,950,000

$

0.32





F-8




Details of options outstanding and exercisable as at November 30, 2017, are as follows:


Exercise price

Grant date

Number of options

outstanding

Number of options

exercisable

$0.05

November 25, 2014

2,500,000

2,500,000

$0.67

January 13, 2015

2,400,000

2,200,000

$0.35

August 5, 2015

2,500,000

2,500,000

$0.35

August 24, 2017

2,050,000

2,050,000

 

 

9,450,000

9,250,000


At November 30, 2017, the weighted average remaining contractual life of the stock options outstanding was 3.52 years.


Warrants


The changes in the number of warrants outstanding during the six-month period ended November 30, 2017, and for the year ended May 31, 2017 are as follows:


 

Six months ended

November 30, 2017

 

Year ended

May 31, 2017

Warrants outstanding, beginning

11,094,605

 

2,000,000

Warrants issued

1,480,000

 

9,094,605

Warrants outstanding, ending

12,574,605

 

11,094,605


Details of warrants outstanding as at November 30, 2017, are as follows:


Exercise price

Grant Date

Number of

warrants

exercisable

$0.25 up to March 3, 2018

$0.40 during the period from March 3, 2018 to March 3, 2019

$0.60 during the period from March 3, 2019 to March 3, 2020

$0.75 during the period from March 3, 2020 to March 3, 2021

March 3, 2016

2,000,000

$0.75 up to October 12, 2018

$1.00 during the period from October 12, 2018 to October 12, 2019

$1.25 during the period from October 12, 2019 to October 12, 2020

$1.50 during the period from October 12, 2020 to October 12, 2021

October 12, 2016

9,094,605

$0.50 up to October 12, 2018

$1.00 during the period from October 12, 2018 to October 12, 2019

$1.50 during the period from October 12, 2019 to October 12, 2020

October 12, 2017

1,480,000

 

 

12,574,605


At November 30, 2017, the weighted average remaining contractual life of the share purchase warrants was 3.67 years.













F-9



Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations


The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.


The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2017, filed with the United States Securities and Exchange Commission (the “SEC”) on August 29, 2017.


Overview


We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our current business direction.


On November 25, 2014, we completed the acquisition of a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments (the “eBalance Technology”).  With our acquisition of the eBalance Technology, we have shifted our business direction to the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.


On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (“Cell MedX Canada”) under the laws of the Province of British Columbia, in anticipation of increased business activity in Canada.


Update on Observational Clinical Study


During the six-month period ended November 30, 2017, Hamilton Medical Research Group, under the guidance of Dr. Richard Tytus, the lead investigator of the clinical study (the “Clinical Study”), Cell MedX Corp. commissioned through Nutrasource Diagnostics Inc. (“Nutrasource”), has completed the Clinical Study and prepared a draft report which at the time of the filing of this Form 10-Q is being finalized by Dr. Tytus.


The Clinical Study was designed to assess the impact of three months of the eBalance therapy, as an adjunct treatment, on HbA1c in thirty (30) Type 1 and Type 2 diabetics.  The secondary endpoints of the Clinical Study were defined to observe changes from baseline and medical history of each Clinical Study subject in the following;


·

Insulin sensitivity

·

Diabetic neuropathy

·

Diabetic foot pain and numbness

·

Wound healing

·

Blood pressure

·

Kidney function

·

Any other changes reported by patients


The Company expects to release the report to the public in the second part of January 2018.







2



Recent Corporate Developments


The following corporate developments occurred during the quarter ended November 30, 2017, and up to the date of the filing of this report:


Private Placement


On October 12, 2017, we closed a non-brokered private placement offering (the “Offering”) at a price of $0.25 per unit, by issuing 1,480,000 units for cash proceeds of $370,000. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of three years after closing at an exercise price of $0.50 per share if exercised during the first year, $1.00 per share if exercised during the second year, and $1.50 per share if exercised during the third year.


Debt Restructuring


On August 24, 2017, we entered into negotiations with our debt holders to convert debt owed by us under the notes payable and for services owed into the shares of our common stock at $0.25 per share. We finalized the debt restructure on October 12, 2017, concurrently with the closing of the Offering. The total of $579,536 was converted into 2,318,144 shares of our common stock. As part of the debt restructuring, Frank McEnulty, our director, President, and our former CEO, converted $120,254 in fees owed to him into 481,016 shares.


Product Development Agreement


On October 16, 2017, we entered into a production development agreement (the “Development Agreement”) with Western Robotics Ltd. (“Western Robotics”) with an objective to enhance our eBalance Pro Wellness device based on the Company’s eBalance microcurrent technology and new findings that became evident as part of the Clinical Study and the Company’s ongoing in-house observations. The Company agreed to pay Western Robotics CAD$250,000 as non-refundable engineering fee, of which CAD$125,000 (USD$97,010) has been paid as of the date of this Quarterly Report on Form 10-Q.


Change in Management


On December 1, 2017, we entered into a management consulting agreement (the “Agreement”) with Dr. Terrance Owen.  Under the terms of the Agreement, Dr. Owen will act as the Company’s Chief Executive Officer for the term of one year, expiring on November 30, 2018, and renewing automatically for consecutive 1-year terms. Dr. Owen will be paid a consulting fee of CAD$16,666 per month.


Dr. Owen obtained a BSc (Honours) in Biology from the University of Victoria, an MSc in Biology from the University of New Brunswick, a PhD in Zoology from the University of British Columbia, and an MBA from Simon Fraser University.


From December 1980 to April 2002 Dr. Owen was the President and a director of Helix Biotech, a laboratory providing DNA identity testing services for paternity, immigration, and forensic cases. From July 1995 to June 1998 Dr. Owen was the President, a director and a co-founder of Helix BioPharma Corp, listed on the TSX Venture Exchange (TSX:HBP), a generic pharmaceutical company.  From 2000 to 2013, Dr. Owen was the President, CEO, director and co-founder of ALDA Pharmaceuticals Corp., an infection control company now named Vanc Pharmaceuticals Inc. (TSX-V:VANC). Dr. Owen was also a co-founder of Champion Pain Care Corporation (OTCQB:CPAI) and was appointed as its CEO from October 2013 to June 2015, as a Director from October 2013 to February 2017, and as CFO from March 2015 to February 2017.


On December 1, 2017, Mr. McEnulty, our director and former Chief Executive Officer, tendered his resignation from his position as CEO. Mr. McEnulty will continue to serve on the Company’s board of directors and as its President.








3



Results of Operations for the Three and Six Months ended November 30, 2017 and 2016


Our operating results for the three- and six-month periods ended November 30, 2017, and 2016, and the changes in the operating results between those periods are summarized in the table below.


 

Three Months Ended

 

Six Months Ended

 

 

November 30,

2017

November 30,

2016

Percentage

Increase /

(Decrease)

November 30,

2017

November 30,

2016

Percentage

Increase /

(Decrease)

Sales

$

-

$

336

(100.0)%

$

-

$

5,704

(100.0)%

Cost of goods sold

 

-

 

180

(100.0)%

 

-

 

3,591

(100.0)%

Gross margin

 

-

 

156

(100.0)%

 

-

 

2,113

(100.0)%

Operating expenses

 

 

 

 

 

 

 

 

 

 

Amortization

 

38,434

 

18,510

107.6%

 

77,557

 

36,521

112.4%

Consulting fees

 

61,422

 

75,607

(18.8)%

 

644,881

 

150,747

327.8%

General and administrative expenses

 

33,586

 

51,239

(34.5)%

 

88,061

 

95,463

(7.8)%

Research and development costs

 

41,491

 

67,173

(38.2)%

 

88,994

 

140,025

(36.4)%

Stock-based compensation

 

6,130

 

29,306

(79.1)%

 

106,931

 

78,203

36.7%

Total operating expenses

 

181,063

 

241,835

(25.1)%

 

1,006,424

 

500,959

100.9%

Accretion expense

 

-

 

7,473

(100)%

 

-

 

13,730

(100.0)%

Interest

 

327

 

5,596

(94.2)%

 

8,241

 

20,991

(60.7)%

Loss on settlement of debt

 

-

 

805,353

(100.0)%

 

-

 

805,353

(100.0)%

Net loss

$

181,390

$

1,060,101

(82.9)%

$

1,014,665

$

1,338,920

(24.2)%


Revenues


We did not generate any revenue during the three- and six-month periods ended November 30, 2017. Our revenue during the comparative periods ended November 30, 2016, consisted of sales of consumables for the spa industry. Due to the current concentration on the research and development of our eBalance Technology and devices based on this technology, as well as the divestiture of Avyonce Cosmedics Inc. (“Avyonce”), our former subsidiary, in our Fiscal 2017, we do not expect to have significant operating revenue in the foreseeable future.


Operating Expenses


During the three-month period ended November 30, 2017, our operating expenses decreased by 25.1% from $241,835 incurred during the three months ended November 30, 2016, to $181,063 incurred during the three months ended November 30, 2017. The decrease was mainly associated with reduced research and development, corporate communication, and consulting fees, as well as decreased stock-based compensation, mainly due to vesting terms of the options granted during our Fiscal 2015 and 2016. These reductions were in part offset by increases to our office expenses and professional fees, as well as amortization we recorded on equipment we use in our observational trials.


During the six-month period ended November 30, 2017, our operating expenses increased by 100.9% from $500,959 incurred during the six months ended November 30, 2016, to $1,006,424 incurred during the six months ended November 30, 2017. The most significant changes were as follows:


·

During the six-month period ended November 30, 2017, our consulting fees increased by $494,134, from $150,747 we incurred during the six-month period ended November 30, 2016 to $644,881 we incurred during the six months ended November 30, 2017. The increase was mainly associated with a fair market value of the options to acquire up to 1,750,000 shares of our common stock we granted to our consultants for business development services.


·

Our research and development fees for the six-month period ended November 30, 2017, decreased by $51,031, from $140,025 we incurred during the six-month period ended November 30, 2016, to $88,994 we incurred during the six months ended November 30, 2017. The lower research and development fees during the comparative period were attributed to moving our production and research activity to Canada, as opposed to having the development outsourced to European manufacturer during the comparative period. In November 2017 we entered into a Development Agreement with Western Robotics to enhance our eBalance Pro Wellness device. We paid Western Robotics $97,010 (CAD$125,000), which at November 30, 2017 were recorded as prepaid research and development fees.



4




·

Our stock-based compensation for the six-month period ended November 30, 2017, increased by $28,728, from $78,203 we incurred during the six months ended November 30, 2016, to $106,931 we incurred during the six months ended November 30, 2017. The stock-based compensation included $89,556 (2016 - $Nil) in fair market value of the options to acquire up to 300,000 shares of our common stock we granted to Ms. Silina pursuant to the stock option agreement with her, and $17,375 (2016 - $66,603) in fair market value of the options to acquire up to 2,400,000 shares of our common stock we granted to Dr. Sanderson pursuant to his option agreement with us. The stock-based compensation for the six-month period ended November 30, 2016, also included $11,600 in fair market value of the options to acquire up to 2,500,000 shares of our common stock we granted to Mr. McEnulty pursuant to the stock option agreement with him.


·

Our general and administrative fees for the six-month period ended November 30, 2017, decreased by $7,402, or 7.8%, from $95,463 we incurred during the six-month period ended November 30, 2016, to $88,061 we incurred during the six months ended November 30, 2017. The largest factors that contributed to this change were associated with decreased corporate communication fees of $2,005 (2016 - $15,541), travel and entertainment expenses of $6,313 (2016 - $14,671), and professional fees of $9,971 (2016 - $12,278). These decreases were in part offset by increased accounting and audit fees of $4,250 (2016 - $740), and foreign exchange expenses of $18,622 (2016 – gain of $1,224).


·

During the six-month period ended November 30, 2017, we recorded $77,557 in amortization on our equipment we use in observations and research and development. During the comparative period ended November 30, 2016, our amortization expense was $36,521. The increased amortization resulted from the change in the estimated useful life of the underlying equipment from three to two years.


Other Items


·

During the six-month period ended November 30, 2017, we accrued $8,241 (2016 - $20,991) in interest associated with the outstanding notes payable. Of this interest, $3,170 (2016 - $5,549) was accrued on notes payable we issued to Mr. Jeffs, a major shareholder.


·

During the six-month period ended November 30, 2016, we recorded $13,730 in accretion expense which resulted from the difference between the 6% stated interest rate and the 77.51% implied interest rate we used to determine the fair value of the proceeds we received pursuant to the $50,000 term loan with Mr. Jeffs. The term loan was fully accreted as at March 3, 2017, as such, we did not record any accretion expense during the six-month period ended November 30, 2017.


·

During the six-month period ended November 30, 2016, we recorded $805,353 in loss on settlement of debt when our debt holders chose to convert $1,006,691 owed to them into units of our common stock as part of the non-brokered private placement financing we closed on October 12, 2016 (the “Offering”). The loss resulted from the difference between the conversion price, being $0.15 per unit, and the fair market value of our common stock on the closing of the Offering, being $0.27 per share. We did not record any loss on settlement of debt associated with the debt restructure we finalized on October 12, 2017.


Liquidity and Capital Resources


Working Capital


 

As at

November 30, 2017

 

As at

May 31, 2017

 

Percentage

Change

Current assets

$

260,323

 

$

100,157

 

159.9%

Current liabilities

 

981,625

 

 

1,463,055

 

(32.9)%

Working capital deficit

$

(721,302)

 

$

(1,362,898)

 

(47.1)%


As of November 30, 2017, we had a cash balance of $108,368, a working capital deficit of $721,302 and cash flows used in operations of $333,204 for the period then ended. During the six-month period ended November 30, 2017, we funded our operations with $370,000 we received from subscriptions to the units of our common stock, which we issued on October 12, 2017, $19,318 (CAD$25,000) we received from Mr. Jeffs, a major shareholder, and $6,000 we received from an unrelated party. See “ Net Cash Provided By Financing Activities ”.



5



We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended November 30, 2017. The amount of cash that we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under these notes and advances payable, or to service our other debt obligations. If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.


Cash Flows

 

Six months ended

November 30,

 

2017

 

2016

Cash flows used in operating activities

$

(333,204)

 

$

(403,305)

Cash flows used in investing activities

 

-

 

 

(14,940)

Cash flows provided by financing activities

 

372,614

 

 

508,938

Effects of foreign currency exchange on cash

 

1,464

 

 

(274)

Net increase in cash during the period

$

40,874

 

$

90,419


Net Cash Used in Operating Activities


Net cash used in operating activities during the six months ended November 30, 2017, was $333,204. This cash was primarily used to cover our cash operating expenses of $294,402, to increase our inventory by $6,017, work in progress recorded as part of inventory by $15,116, and current assets by $99,028. The cash used for current assets included $97,010 (CAD$125,000) we paid under our Development Agreement to enhance our eBalance Pro Wellness device. In addition, we used our cash to reduce our accrued liabilities by $74,719. These uses of cash were offset by increases in our accounts payable and amounts due to related parties of $66,244 and $30,246, and $59,588 in unearned revenue associated with a deposit we received on eBalance distribution contract.


Net cash used in operating activities during the six months ended November 30, 2016, was $403,305. This cash was primarily used to cover our cash operating expenses of $388,386, to increase our current assets by $40,213, which included partial payments we made on manufacturing of our eBalance Pro Wellness devices, and to reduce our accrued liabilities by $29,553. These uses of cash were offset by decrease in our inventory of $797, and by increases in our accounts payable and amounts due to related parties of $12,358 and $30,221, respectively. In addition, we recorded $11,471 in unearned revenue associated with the deposit we received on the eBalance Pro Wellness device, which we received in December 2016.


Non-cash transactions


During the six-month period ended November 30, 2017, our net loss was affected by the following expenses that did not have any impact on cash used in operations:


·

$106,931 in stock-based compensation, of which $89,556 was associated with the fair value of the options to purchase up to 300,000 shares of our common stock we granted to Ms. Silina, our CFO, as compensation for her services; and $17,375 was associated with the fair value of the options to purchase up to 2,400,000 shares of our common stock we granted to Dr. Sanderson, our Chief Medical Officer;


·

$522,407 in fair value of option to acquire up to 1,750,000 shares our common stock we issued for consulting services;


·

$8,241 in interest we accrued on the outstanding notes payable. Of this interest, $3,170 was accrued on the notes payable we issued to Mr. Jeffs, a major shareholder;


·

$77,557 in amortization expense we recorded on the equipment we use in our research of the eBalance Technology; and


·

$5,127 in unrealized foreign exchange, which resulted from fluctuations of Canadian dollar and European Euro denominated transactions.



6



During the six-month period ended November 30, 2016, our net loss was affected by the following expenses that did not have any impact on cash used in operations:


·

$805,353 in loss on settlement of debt we recorded when our debt holders chose to convert $1,006,691 owed to them into units of our common stock as part of the Offering. The loss resulted from the difference between the conversion price, being $0.15 per unit, and the fair market value of our common stock on the closing of the Offering, being $0.27 per share.

·

$78,203 in stock-based compensation, of which $66,603 was associated with the fair value of the options to purchase up to 2,400,000 shares of our common stock we granted to Dr. Sanderson as compensation for his appointment as our Chief Medical Officer; and $11,600 was associated with the fair value of the options to purchase up to 2,500,000 shares of our common stock we granted to Mr. Frank McEnulty, our former CEO and President;

·

$20,991 in interest we accrued on the outstanding notes payable. Of this interest, $5,549 was accrued on the notes payable we issued to Mr. Jeffs, a major shareholder;

·

$13,730 in accretion expense which resulted from the difference between the 6%  stated interest rate and the 77.51% implied interest rate we used to determine the fair value of the proceeds we received pursuant to the $50,000 term loan with Mr. Jeffs; and

·

$36,521 in amortization expense we recorded on the equipment we use in our research of the eBalance Technology.

The above expenses were in part offset by $4,264 decrease in the loss on foreign exchange, which resulted from fluctuations of Canadian dollar and European Euro denominated transactions.


Net Cash Provided by Financing Activities


During the six-month period ended November 30, 2017, we borrowed a total of $19,318 (CAD$25,000) from a major shareholder and $6,000 from an unrelated party. The loans are unsecured, payable on demand and bear interest at 6% per annum, compounded monthly. In addition to the loans, we received $370,000 from subscriptions to the units of our common stock under the Offering, which we closed on October 12, 2017. During the same period we repaid net of $22,704 in non-interest bearing advances with an unrelated party.


On September 15, 2017, we received a notice from Mr. Jeffs that he had assigned the rights to $7,984 due to him under the demand notes payable and $54,516 due to him under the Term Loan to two unaffiliated parties. The assignees notified the Company of their intention to convert the debt acquired by them from Mr. Jeffs into the shares of the Company’s common stock as part of the proposed debt restructuring initiative (the “Debt Restructuring”), which we completed on October 12, 2017.


During the six-month period ended November 30, 2016, we borrowed a total of $75,000 from unrelated parties and $73,754 (CAD$96,500) from a major shareholder. These loans were unsecured, payable on demand and bore interest at 6% per annum, compounded monthly. In addition to the loans, we received $2,684 in non-interest bearing advances from an unrelated party. During the same period we received $357,500 from subscriptions to the units of our common stock under the offering, which we closed on October 12, 2016.


Net Cash Used in Investing Activities


We did not have any investing activities during the six-month period ended November 30, 2017.


During the six-month period ended November 30, 2016, we paid $14,940 for the equipment which is being used in our observational studies.


Going Concern


The notes to our unaudited interim consolidated financial statements at November 30, 2017, disclose our uncertain ability to continue as a going concern. We are a development stage company with limited operations. To date we have been able to generate only minimal revenue from the operations of our former wholly owned subsidiary, Avyonce, which we divested in January 2017. Our research and development plans for the near future will require large capital expenditures, which we are planning to mitigate through equity or debt financing.



7



We have accumulated a deficit of $5,518,708 since inception and increased financing will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our unaudited interim consolidated financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.


Off-Balance Sheet Arrangements


None.


Critical Accounting Policies


An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.


Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure


None.


Item 3. Quantitative and Qualitative Disclosure about Market Risk


None


Item 4. Controls and Procedures


Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.


An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2017. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.


During the quarter ended November 30, 2017, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.







8



PART II - OTHER INFORMATION


Item 1. Legal Proceedings


None.


Item 1A. Risk Factors


There is a high degree of risk associated with investing in our securities.  Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.


The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment.  We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.


Risks Associated with our Company and our Industry


We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments.  Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.


The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.


We are subject to numerous governmental regulations which can increase our costs of developing our eBalance Technology and products based on this technology.


Our products may be subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.


Changes in the health care regulatory environment may adversely affect our business.


A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.





9



Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.


Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.


Our research and development efforts may not result in the development of commercially successful products based on our eBalance Technology, which may hinder our profitability and future growth.


Our eBalance Technology is currently in the research and development stage as are our planned products incorporating this technology.  In order to develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.


Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.


Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.


New products and technological advances by our competitors may negatively affect our results of operations.


Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.


Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.


Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.


Inability to attract and maintain key personnel may cause our business to fail.


Success depends on the acquisition of key personnel.  We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants.  If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.



10



We are recently formed, lack an operating history and to date have generated only minimal revenues.  If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.


We are a recently formed company and to date have generated only minimal revenues through sales of Spa equipment and services through our former wholly owned subsidiary, Avyonce, which we divested of in January of 2017. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing.  We have a very limited operating history and thus our progress as well as potential future success cannot be reasonably estimated.  Success has yet to be proven. We have yet to prove our eBalance Technology through clinical trials and we have yet to develop any products through which we would be able to start generating revenue. Financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance Technology, of which there is no assurance.  As a new business we face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties.  Since inception, we have accumulated deficit of $5,518,708 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.


We need to acquire additional financing or our business will fail.


We must obtain additional capital or our business will fail. In order to continue development of our eBalance Technology and to successfully complete clinical trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on.  We currently have no arrangements for additional financing.  We may also have to borrow large sums of money that require substantial capital and interest payments.


Risks related to our stock


We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.


Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue.  However there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.


There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.


Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.


Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.


Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations.  Liquidity may be low despite there being a market, making it difficult to get a return on the investment.  The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.


Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.


The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.




11



Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:


·

contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

·

contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws;

·

contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

·

contains a toll-free telephone number for inquiries on disciplinary actions;

·

defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and

·

contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation.


The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.


We have not paid nor anticipate paying cash dividends on our common stock.


We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history.  The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:


(a)

we would not be able to pay our debts as they become due in the usual course of business; or

(b)

except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.


We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds


On October 12, 2017, we closed our non-brokered private placement offering (the “Offering”) at a price of $0.25 per unit (each "Unit"), by issuing 1,480,000 Units for total gross proceeds of $370,000.


Each Unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of three years after closing at an exercise price of $0.50 per share if exercised during the first year, $1.00 per share if exercised during the second year, and $1.50 per share if exercised during the third year.


The Units were issued pursuant to the provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act.




12




On October 12, 2017, we completed our debt restructuring initiative by converting a total of $459,282 we owed under our notes payable and $120,254 under services payable into 2,318,144 shares of our common stock at $0.25 per share.  


1,837,128 shares were issued pursuant to the provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act. Remaining 481,016 shares issued to a director of the Company were issued pursuant to the exemption from the registration requirements of the Securities Act of 1933 provided by Rule 506 of Regulation D.


Item 3. Defaults upon Senior Securities


None.


Item 4. Mine Safety Disclosures


None.


Item 5. Other Information


None.


Item 6. Exhibits


Exhibit

Number

 

Description of Document

3.1

 

Articles of Incorporation (2)

3.2

 

Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(5)

3.3

 

Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(5)

3.4

 

Bylaws (1)

4.1

 

Specimen Stock Certificate (1)

10.1

 

Letter Agreement dated August 29, 2014 among Sports Asylum, Inc., Jean Arnett, Brad Hargreaves and XC Velle Institute Inc. (4)

10.2

 

Consulting Agreement dated September 1, 2014 among Sports Asylum, Inc. and Jean Arnett.

10.3

 

Consulting Agreement dated September 1, 2014 among Sports Asylum, Inc. and Brad Hargreaves.

10.4

 

Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6)

10.5

 

First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(7)

10.6

 

Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(8)

10.7

 

Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)

10.8

 

Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves.(9)

10.9

 

First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)

10.10

 

First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves. (9)

10.11

 

Management Consulting Agreement dated January 13, 2015 among Cell MedX Corp., and Dr. John Sanderson, MD.(10)

10.12

 

Stock Option Agreement dated December 12, 2014 among Cell MedX Corp. and Dr. John Sanderson, MD. (10)

10.13

 

Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(11)




13




Exhibit

Number

 

Description of Document

10.14

 

eBalance Prototype Development Agreement dated October 1, 2015 among Cell MedX Corp., and Claudio Tassi. (12)

10.15

 

Non-binding Letter of Intent dated December 4, 2015 to Enter into Development Agreement and License Agreement among Cell MedX Corp., Claudio Tassi, and Bioformed Aesthetic S.L.(13)

10.16

 

Loan Agreement and Note Payable dated February 4, 2016, among Cell MedX Corp., and Tradex Capital Corp.

10.17

 

Loan Agreement and Note Payable dated March 2, 2016, among Cell MedX Corp., and Tradex Capital Corp.

10.18

 

Loan Agreement dated March 3, 2016 between Richard Norman Jeffs and Cell MedX Corp. (14)

10.19

 

Loan Agreement and Note Payable dated March 10, 2016, among Cell MedX Corp., and Tradex Capital Corp. (15)

10.20

 

Loan Agreement and Note Payable dated March 30, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)

10.21

 

Loan Agreement and Note Payable dated March 31, 2016 among Cell MedX Corp., and Richard N. Jeffs. (16)

10.22

 

Loan Agreement and Note Payable dated April 29, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.23

 

Loan Agreement and Note Payable dated June 1, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)

10.24

 

Loan Agreement and Note Payable dated June 2, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.25

 

Loan Agreement and Note Payable dated June 29, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)

10.26

 

Loan Agreement and Note Payable dated June 30, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.27

 

Loan Agreement and Note Payable dated August 8, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.28

 

Loan Agreement and Note Payable dated August 22, 2016, among Cell MedX Corp., and Tradex Capital Corp. (16)

10.29

 

Letter Agreement dated September 26, 2016, between Jean Arnett, Brad Hargreaves and Cell MedX Corp. (17)

10.30

 

Loan Agreement and Note Payable dated January 6, 2017, among Cell MedX Corp., and Richard N. Jeffs.(18)

10.31

 

Loan Agreement and Note Payable dated February 7, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19)

10.32

 

Loan Agreement and Note Payable dated February 27, 2017, among Cell MedX Corp., and Richard N. Jeffs. (19)

10.33

 

Loan Agreement and Note Payable dated January 11, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)

10.34

 

Loan Agreement and Note Payable dated January 13, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)

10.35

 

Loan Agreement and Note Payable dated February 14, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)

10.36

 

Loan Agreement and Note Payable dated March 8, 2017, among Cell MedX Corp., and Tradex Capital Corp. (19)

10.37

 

Loan Agreement and Note Payable dated April 18, 2017, among Cell MedX Corp., and Perla Capital Inc. (19)

10.38

 

Loan Agreement and Note Payable dated May 5, 2017, among Cell MedX Corp., and Tradex Capital Corp. (19)

10.39

 

Loan Agreement and Note Payable dated July 12, 2017, among Cell MedX Corp., and Richard N. Jeffs. (20)

10.40

 

Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina (20)




14




Exhibit

Number

 

Description of Document

10.41

 

Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp. (20)

10.42

 

Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco (20)

10.43

 

Product Development Agreement for eBalance dated October 16, 2017, among Cell MedX Corp. and Western Robotics Ltd.

14.1

 

Code of Ethics (3)

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

 

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

 

Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

 

The following materials from this Quarterly Report on Form 10-Q for the three- and six-month periods ended November 30, 2017 and 2016 formatted in XBRL (extensible Business Reporting Language):

 

 

(1) Consolidated Balance Sheets at November 30, 2017 (unaudited), and May 31, 2017.

 

 

(2) Unaudited Condensed Interim Consolidated Statements of Operations for the three- and six-month periods ended November 30, 2017 and 2016.

 

 

(3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit as at November 30, 2017.

 

 

(3) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Six-month Periods ended November 30, 2017 and 2016.


(1)

Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC  on July 13, 2010

(2)

Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010

(3)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with SEC on August 26, 2014

(4)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on September 5, 2014

(5)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014

(6)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014

(7)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014

(8)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014

(9)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2014

(10)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 13, 2015

(11)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015

(12)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2016

(13)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 15, 2015

(14)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016

(15)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2016

(16)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2016

(17)

Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2016

(18)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2017

(19)

Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 29, 2017

(20)

Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017





15




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



  

Cell MedX Corp.

  

  

Date: January 16, 2018

By:

/s/ Terrance Owen

  

  

Terrance Owen, PhD, MBA

  

  

Chief Executive Officer and Director

  

  

(Principal Executive Officer)

  

  

 

Date: January 16, 2018

By:

/s/Yanika Silina

  

  

Yanika Silina

  

  

Chief Financial Officer

  

  

(Principal Accounting Officer)

 





































16


Product Development Agreement for

Ebalance


between


WESTERN ROBOTICS LTD. a British Columbia corporation with offices at #215-12837 76 Avenue, Surrey, B.C., Canada V3W 2V3, hereinafter “Western Robotics”;


and


CELL MEDX  CORP . a Nevada corporation with offices at #446-123 West Nye Ln, Carson City, Nevada, 89706, hereinafter “CELL MEDX”







This Development Agreement (the “Agreement”) is entered into and effective as of October 16, 2017 (the “Effective Date”) by and between Western Robotics and CELL MEDX, hereinafter the “Parties”.


Western Robotics and CELL MEDX  enter into this Agreement regarding the redevelopment of the EBALANCE in accordance with the terms and subject to the conditions of this Agreement. This Agreement consists of the attached Agreement and Exhibit A (“Payment for Development Work”).




IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date written above and both Parties agree to be bound by the enclosed terms and conditions.


Western Robotics Ltd.

CELL MEDX  CORP.




By: /s/Bounchanh Thanasack




By: /s/ Frank McEnulty

Name:  Bounchanh Thanasack

Name: Frank McEnulty

Title:  Director

Title: President








1

WR Electronics Development Agreement




AGREEMENT


1. DEFINITIONS


1.1

“Product” shall mean an EBALANCE to be developed by CELL MEDX with development assistance from Western Robotics for manufacture and distribution by CELL MEDX under the terms of this Agreement and described in Section 2.3.


1.2

“Project” shall mean the design, redevelopment and manufacture of the EBALANCE in accordance with the Product Specifications and Responsibilities herein.


1.3

“Western Robotics Project Deliverables” shall mean the designs, schematics, prototypes, and other documentation delivered by Western Robotics to CELL MEDX as a result of Western Robotics’ successful completion of Project Specifications, Development Work and Project Deliverables as per schedule A.


1.4

“Western Robotics Technology” shall mean the know-how and technology developed by Western Robotics prior to or independent of the Project being performed under this Agreement.


1.5

“Development Work” shall mean that part of Western Robotics Technology which is provided to CELL MEDX as part of this Agreement.  Development Work shall refer to only that part of Western Robotics Technology which is delivered by Western Robotics to CELL MEDX  as the result of successful completion of the Project, being incorporated by Western Robotics within Western Robotics Project Deliverables and being incorporated by CELL MEDX in the Product.


1.6

“Confidential Information” shall mean (i) any trade secrets relating to either party’s product plans, designs, costs, prices and names, finances, marketing plans, business opportunities, personnel, research development, or know-how; (ii) any written information designated by the disclosing party as confidential and marked as confidential; (iii) the terms, conditions, and existence of this Agreement except by written consent of the other party. “Confidential Information” shall not include information that is or becomes generally known or available by publication, commercial use, otherwise through no fault of the receiving party.


2. DEVELOPMENT


2.1

Western Robotics Contribution. During the course of the Project, Western Robotics shall assist in the development of the Product in accordance with the Product Specifications and Western Robotics Responsibilities contained herein.


2.2

Product Specifications. The Project as defined herein will result in the development of a Product specified by CELL MEDX as an “EBALANCE” that generates micro current.  The Product, as defined by CELL MEDX, will be a medical product that generates micro current into the human body through the skin.


2.3

Western Robotics Responsibilities. Western Robotics will be responsible for the aspects of the Project, as defined in and mutually agreed upon by the Parties in a separate Exhibit A.


3. PAYMENT FOR DEVELOPMENT


CELL MEDX shall pay Western Robotics for participation in the Project, including development and deliverables in the amounts as set forth in and mutually agreed upon by the Parties in Exhibit A.  The fee associated with each phase of the Project is due upon initiation of that phase. The remainder of the fee associated with each phase is due upon successful completion of that phase. Continuation from one phase to the next is contingent upon approval by CELL MEDX and subsequent agreement by both Parties upon a formal definition of that phase.



2

WR Electronics Development Agreement




4. CONFIDENTIALITY


Each party shall protect the other’s Confidential Information from unauthorized dissemination and use with the same degree of care that such party uses to protect its own like information. Neither party will use the other’s Confidential Information for purposes other than those necessary to directly further the purposes of this Agreement. Neither party will disclose to third parties the other’s Confidential Information without the prior written consent of the other party.


5. TERMINATION


5.1

Term. The term of this Agreement shall commence as of the Effective Date and shall continue until terminated as provided in this section.


5.2

Termination. CELL MEDX can terminate this Agreement with or without cause at any time by providing Western Robotics written notice of such cancellation. Upon receipt of such notice prior to Project completion, Western Robotics will discontinue development work on the Project and void all granted license rights to CELL MEDX.  If termination occurs prior to completion of the development phase of the Project, CELL MEDX shall pay for all services performed and expenses incurred by Western Robotics up to the date of receipt of the cancellation notice.


5.3

Breach. Upon a material breach of any terms of this Agreement, the non-breaching party can terminate this Agreement upon 30 days written notice if such a breach is not cured within said 30 day period.


5.4

Effect of Termination. In the event of termination or expiration of this Agreement for any reason, Sections 1, 4, 6, 7, and 9 shall survive termination. Any termination, for breach or otherwise, shall not affect any Products manufactured, in whole or in part, prior to the date of termination or expiration.


6. WARRANTY


6.1

Western Robotics represents, warrants, and agrees that it is currently a corporation duly organized, validly existing, and in good standing under the laws of British Columbia, having full right, power, and authority, corporate and otherwise, to purchase, own, and license the Development Work.


6.2

Western Robotics warrants that title to all software, firmware, and API’s delivered to CELL MEDX pursuant to this Agreement shall be free and clear of all liens, encumbrances, security interest, or other adverse interests or claims. Western Robotics warrants that none of the Development Work provided as a deliverable by this Agreement knowingly infringes any currently issued patent, copyright, or trade secret of a third party.  Western Robotics only warrants Development Work in isolation as delivered and will not be liable in any way that Development Work when implemented in combination with other methods or technologies not explicitly provided by and explicitly licensed by Western Robotics, creates a system or practice method which infringes a copyright, patent, or trade secret of a third party.


7. INDEMNIFICATION


7.1

Western Robotics will indemnify CELL MEDX, its officers, directors, shareholders, employees, agents, and successors in interest for, from, and against liabilities, actions, claims, suits, damages, costs, and expenses incurred in connection with a claim for infringement which constitutes a breach of the foregoing Western Robotics warranties up to the amount of payment issued to Western Robotics to perform its duties under this agreement provided that Western Robotics is notified promptly in writing of such a claim or controversy.  Western Robotics shall have sole control over the defense and settlement of such a claim so long as no settlement adversely affects CELL MEDX ability to exercise its rights under this Agreement.  All expenses incurred by Western Robotics in defending  and settling  such a claim shall be provided by CELL MEDX.



3

WR Electronics Development Agreement





7.2

CELL MEDX  will indemnify and hold harmless Western Robotics, its officers, directors, shareholders, employees, agents, and successors in interest, for, from, and against any and all liabilities, actions, claims, suits, losses, damages, costs, and expenses, including reasonable attorney’s fees, incurred in connection with the manufacture, distribution, or sale by CELL MEDX  of the Product or future products incorporating the Development Work, in any country, except as specifically excluded by the indemnification in 7.1 above wherein an infringement or claim of infringement arises from the use of Development Work in ways specifically warranted in 6.2 above.  CELL MEDX shall have sole control over the defense and settlement of such a claim so long as no settlement adversely affects Western Robotics ability to exercise its rights under this Agreement.  


7.3

Notwithstanding anything to the contrary contained herein, this indemnification shall survive termination of this Agreement.


8. DISPUTE RESOLUTION


If there is a disagreement or dispute between the parties with respect to this Agreement or the interpretation thereof, such disagreement or dispute will be referred to binding arbitration to be conducted by a single arbitrator pursuant to the provisions of the Commercial Arbitration Act (British Columbia) and any amendments thereto, and the determination of such arbitrator will be final and binding upon the parties.


9. GENERAL


9.1

Limitation of Liabilities. Neither party shall be liable for any indirect, incidental, consequential, punitive, or special damages, even if such party has been advised of the possibility of such damages.  Independent of, severable from and to be enforced independently of any other enforceable or unenforceable provision of this Agreement, in no event will Western Robotics aggregate liability to CELL MEDX with respect to any and all claims at any and all times arising from or related to the Product, in contract, tort, or otherwise exceed the actual consideration paid by CELL MEDX to Western Robotics for its development services under this Agreement.


9.2

Assignment. This Agreement, and any rights or obligations hereunder shall not be assignable by contract or by operation of law without the prior written approval of the other party. Merger or acquisition of either party by a third party shall not be deemed an assignment.


9.3

Notice. Any notice required or permitted to be given there under shall be in writing and shall be (i) personally delivered, including by messenger or courier; or (ii) sent by Certified Mail, postage prepaid; or (iii) transmitted by fax with a copy to be mailed on the same or next business day, as provided for under clause (ii) above to the following address; For Cell MedX; Cell MedX Corp. C/O Suite 820, 1130 West Pender Street Vancouver, B.C. V6E, 4A4, email yana@cellmedx.com; for Western Robotics Ltd. Suite 215-12837 76 Avenue, Surrey, B.C. Canada V3W 2V3. Each party may change such party’s address for notices by notices given in accordance with this Section 9.3.


9.4

Governing Law. This Agreement shall be governed in and construed and enforced in accordance with the laws of the Province of British Columbia.


9.5

Independent Contractor. Western Robotics and CELL MEDX acknowledge that each is an independent contractor and that under this Agreement neither Western Robotics nor CELL MEDX shall be considered for any purpose to be the agent, partner, franchisor, franchisee, or joint venture of the other. Nor shall Western Robotics or CELL MEDX have any obligation or responsibility to act on behalf or in the name of the other, of the power or authority to bind the other in any manner whatsoever. Any representation to the contrary by Western Robotics or CELL MEDX, or the employees or agents of either, shall be sufficient grounds for termination of this Agreement for cause.



4

WR Electronics Development Agreement





9.6

Severability. If any provision of this Agreement is determined to be illegal or unenforceable, then such provisions are hereby waived to the extent necessary for this Agreement to be otherwise enforceable.


9.7

Multiple Counterparts. This Agreement may be executed by facsimile and in several counterparts, all of which taken together will constitute one single Agreement between the parties.


9.8

Entire Agreement . This Agreement and the schedules attached hereto, together with any Work Statements agreed upon and issued from time to time hereunder, constitute the entire agreement between the parties hereto with respect to the subject matter hereof, and supersedes and replaces all prior or contemporaneous understandings or agreements, written or oral, regarding such subject matter. Unless otherwise provided herein, this Agreement may not be modified, amended, rescinded, or waived, in whole or part except by a written instrument signed by the duly authorized representatives of both parties and expressly referring to this Agreement.


































5

WR Electronics Development Agreement




Exhibit A

Payment for Development Work Performed by Western Robotics Ltd.


Project Specifications:


Definitions

These terms will be used throughout the rest of the document:

Action – Series of electric pulses to be administered to the patient

Treatment – Named collection (e.g. Pain and Wellness Management) of Actions


Description

The proposed redevelopment of the Product is specified by CELL MEDX as an “EBALANCE” medical product that generates micro current into the human body through the skin.  The Development Work of the EBALANCE is to extract existing features from the EBALANCE Italian & Ukrainian version prototypes to incorporate into one board design and output the same waveform outputs as the Italian version.


The device applies a treatment by executing each action in a given order, where each action comprises of a series of electrical pulses to be administered to the patient’s skin. The current number of possible actions for each treatment is 26.  As each action is administered, the device will collect measurements. The PC software will allow the user to select a treatment, trigger device execution, and display the measurements.


Development Work

There are several phases that are involved in the Development Work that is summarized as follows:

·

Extract same hardware design from existing EBALANCE Italian version prototype and use:

o

analog op-amp filter circuitry and feedback circuitry

o

all circuitry found during the hardware reverse engineering process

·

Source an external medical grade certified power supply

·

Use Western Robotics selected micro-controller and program its firmware to mimic EBALANCE Italian prototype s micro-controller function for Wellness and Pain treatments (total of 52 possible waveforms with +/- 20% linear adjustable power, may not much the Italian version)

·

Compare and confirm output waveforms and frequencies from developed prototype match Italian version prototype

·

Re-design printed circuit board to accommodate new micro-controller and to match  Ukrainian version s printed circuit board s mounting holes and size.

·

Develop new software interface and protocol with developed hardware prototype


Software Design

For a Windows application, compatible with Windows 7 to 10.


The user interface will be completely re-designed  focusing on functionality, readability, and user-friendliness. Western Robotics may re-use certain elements of the Ukrainian or Italian version at the customer’s request..


User interface components will include

·

·

Menu listing treatments to run

o

Pain Management

o

Wellness

·

 

·

Action number

·

Results graph

·

Start/stop toggle button

·

Mute/unmute toggle button for the built in buzzer

·

Set/Reset treatment usage counter, total counter and charge counter



6

WR Electronics Development Agreement





Exhibit A Continued


Execution Steps

1.

User chooses treatment by name

2.

User presses start button to begin

3.

For each action:

a.

Action number is displayed

b.

Software sends action number and its series of pulses to device, and waits on the response

c.

Device returns series of measurements

d.

Software displays on the graph each measurement as a bar along a moving timeline, where the bar has a height and colour that represents its relative magnitude

e.

Start and Confirm button to confirm purchase of treatment



Results Graph

The data will be received from the device after each action is started, in the form of discrete values over a period of time. Each value will appear as a vertical bar in the graph, where the X-axis represents time and the Y-axis represents magnitude. Each bar will also be coloured to indicate the efficacy of the results, according to their relative magnitude: red for low values, yellow, or green for high values (actual values TBD).


Sound

The user can, at any time, click the buzzer mute/unmute button. The software will send a signal to the device with the user’s choice, and the device will turn its sound on or off.



Project Deliverables:


1. Product Prototype

Eight fully functional sets of printed circuit board assemblies. The features included are:


q

Design features same as EBALANCE Italian version prototype.  Refer to Development Work.

q

Board size similar to EBALANCE Ukrainian version prototype.

q

Input and output ports similar to EBALANCE prototypes.

q

New software interface (Windows 7 and up compatible) with new custom protocol for Product prototype.  Refer to Software Design above.

q

Provides same Wellness and Pain treatments total of 52 waveforms.

q

New Source medical grade certified external power supply

q

Integrated USB port.


Emissions and certification approvals such as FCC, CSA, CE and/or any other compliant testing are not included as part of the Project.

    

2. Product Documentation

Product electrical schematic design files, bill of materials, printed circuit board Gerber files, firmware source code, frequencies and wave forms documentation, programming files, PC software application and source code files.






7

WR Electronics Development Agreement




Exhibit A Continued


Terms of payment:


There will be 3 phases of payment :

1.

CELL MEDX provides first Initial payment of $10,000 (Paid October 16, 2017)t.

a.

Western Robotics allocates time to initiate project

2.

Second l payment of $115,000 within 2 weeks of signed Agreement or when Western Robotics confirms start of Development Work (whichever comes first)

a.

Western Robotics confirms design initiation.

b.

Western Robotics delivers in-house prototypes for CELL MEDX for approval

c.

Completion of eight prototypes to be delivered in approximately 5 months including required software (Tentative upon discrepancies).

3.

CELL MEDX provides final payment of $125,000 upon approval and completion fully functional prototype boards.  Western Robotics will:

a.

fix any remaining bugs or adds minor additional features upon discretion.

b.

provide final schematic design, firmware and PCB layout gerber files and documentation.


Total non-refundable engineering fee of $250,000 CAD.

All additional delivery/shipping cost to be provided by client.






























8

WR Electronics Development Agreement



CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Terrance Owen, certify that:

 

1.  I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2017, of Cell MedX Corp.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  January 16, 2018


/s/ Terrance Owen

Terrance Owen

Chief Executive Officer

(Principal Executive Officer)



CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Yanika Silina, certify that:

 

1.  I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2017, of Cell MedX Corp.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 16, 2018


/s/Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)




CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:


(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: January 16, 2018


/s/ Terrance Owen

Terrance Owen

Chief Executive Officer and President

(Principal Executive Officer)


























CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:


(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: January 16, 2018


/s/Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)